

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5010025

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ANDREW MCDONALD	01/20/2017
SHAWN QIAN	01/20/2017
RECEIVING PARTY DATA	
Name:	LIFESCI PHARMACEUTICALS, INC.
Street Address:	WHITEPARK HOUSE, WHITEPARK ROAD
City:	BRIDGETOWN, ST. MICHAEL
State/Country:	BARBADOS
Postal Code:	BB11135
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16009093
CORRESPONDENCE DATA	
Fax Number:	(650)493-6811
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(650) 493-9300
Email:	patentdocket@wsgr.com, randico@wsgr.com
Correspondent Name:	WILSON SONSINI GOODRICH & ROSATI
Address Line 1:	650 PAGE MILL ROAD
Address Line 4:	PALO ALTO, CALIFORNIA 94304
ATTORNEY DOCKET NUMBER:	48367-711.301
NAME OF SUBMITTER:	ROSE ANDICO
SIGNATURE:	/Rose Andico/
DATE SIGNED:	06/15/2018
Total Attachments: 2	
source=48367-711.301 - Signed Assignment from parent#page1.tif	
source=48367-711.301 - Signed Assignment from parent#page2.tif	

WHEREAS, the undersigned:

1. Andrew MCDONALD
250 West 55th Street, Suite 16B
New York, NY 10019, US

2. Shawn QIAN
1175 Chess Drive, Suite 206
Foster City, CA 94404, US

(hereinafter "Inventor(s)), have invented certain new and useful improvements in

THERAPEUTIC INHIBITORY COMPOUNDS

- ☐ for which a United States patent application is filed on even date herewith;
☒ for which application serial number 15/199,785 was filed on June 30, 2016, in the United States Patent and Trademark Office;
☐ for which a PCT application serial number _____ was filed on _____ in the [] Receiving Office of the Patent Cooperation Treaty;
☐ for which application serial number _____ was filed on _____ in the _____ Patent Office;
☐ for which an application was filed upon which a United States Patent issued on _____, as U.S. Patent No. _____; or
☐ for which a PCT application will be filed on or before [insert 12-month date] in the [] Receiving Office of the Patent Cooperation Treaty

which will claim priority to []

(hereinafter, "Application(s)"). The term "Application(s)" also includes all patent applications that share or claim priority to or from the above application(s).

WHEREAS, LifeSci Pharmaceuticals, Inc., an entity incorporated in Barbados, having a place of business at Whitepark House, Whitepark Road, Bridgetown, St. Michael, BB11135 Barbados, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).

2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

4. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.


6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

PATENT ASSIGNMENT

Docket Number 48367-703.201


IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: 01-20-2017



Andrew MCDONALD

Date: 01-20-2017




Shawn QIAN

RECEIVED AND AGREED TO BY ASSIGNEE:

LIFESCI PHARMACEUTICALS, INC.

Date: 01-20-2017


By: _____
Andrew McDonald, Ph.D.
Chief Executive Officer